Christopher J R Illingworth
Overview
Explore the profile of Christopher J R Illingworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1549
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fozard J, Thomson E, Illingworth C
J R Soc Interface
. 2024 Aug;
21(217):20240168.
PMID: 39109454
Viruses that infect animals regularly spill over into the human population, but individual events may lead to anything from a single case to a novel pandemic. Rapidly gaining an understanding...
2.
Sinclair P, Zhao L, Beggs C, Illingworth C
Nat Commun
. 2024 Apr;
15(1):3540.
PMID: 38670957
The transmission bottleneck describes the number of viral particles that initiate an infection in a new host. Previous studies have used genome sequence data to suggest that transmission bottlenecks for...
3.
Illingworth C, Guerra-Assuncao J, Gregg S, Charles O, Pang J, Roy S, et al.
Virus Evol
. 2024 Mar;
10(1):veae001.
PMID: 38486802
Mutagenic antiviral drugs have shown promise against multiple viruses, but concerns have been raised about whether their use might promote the emergence of new and harmful viral variants. Recently, genetic...
4.
Flowers P, Leiser R, Mapp F, McLeod J, Stirrup O, Illingworth C, et al.
Br J Health Psychol
. 2023 May;
28(4):1011-1035.
PMID: 37128667
Purpose: The aim of this study was to conduct a process evaluation of a whole-genome sequence report form (SRF) used to reduce nosocomial SARS-CoV-2 through changing infection prevention and control...
5.
Brevini T, Maes M, Webb G, John B, Fuchs C, Buescher G, et al.
Nature
. 2022 Dec;
615(7950):134-142.
PMID: 36470304
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for COVID-19 that complements vaccination. However, the mechanisms that control...
6.
Kemp S, Collier D, Datir R, Ferreira I, Gayed S, Jahun A, et al.
Nature
. 2022 Jul;
608(7922):E23.
PMID: 35864233
No abstract available.
7.
Nickbakhsh S, Hughes J, Christofidis N, Griffiths E, Shaaban S, Enright J, et al.
Sci Rep
. 2022 Jul;
12(1):11735.
PMID: 35853960
Whole genome sequencing of SARS-CoV-2 has occurred at an unprecedented scale, and can be exploited for characterising outbreak risks at the fine-scale needed to inform control strategies. One setting at...
8.
Stejskal L, Kalemera M, Lewis C, Palor M, Walker L, Daviter T, et al.
Elife
. 2022 Jul;
11.
PMID: 35796426
E1 and E2 (E1E2), the fusion proteins of Hepatitis C Virus (HCV), are unlike that of any other virus yet described, and the detailed molecular mechanisms of HCV entry/fusion remain...
9.
Kemp S, Cheng M, Hamilton W, Kamelian K, Singh S, Rakshit P, et al.
Sci Rep
. 2022 Jun;
12(1):10492.
PMID: 35729228
Breakthrough infections with SARS-CoV-2 Delta variant have been reported in doubly-vaccinated recipients and as re-infections. Studies of viral spread within hospital settings have highlighted the potential for transmission between doubly-vaccinated...
10.
Illingworth C, Hamilton W, Jackson C, Warne B, Popay A, Meredith L, et al.
Mol Biol Evol
. 2022 Feb;
39(3).
PMID: 35106603
Identifying linked cases of infection is a critical component of the public health response to viral infectious diseases. In a clinical context, there is a need to make rapid assessments...